Differential tumor-targeting abilities of three single-domain antibody formats

Cancer Letters

Volumn 289, Issue 1, 2010, Pages 81-90

  Bell, Andrea ^a   Wang, Zheng J ^b   Arbabi Ghahroudi, Mehdi ^a   Chang, Tingtung A ^b   Durocher, Yves ^a   Trojahn, Ulrike ^a   Baardsnes, Jason ^a   Jaramillo, Maria L ^a   Li, Shenghua ^a   Baral, Toya N ^a   O'Connor McCourt, Maureen ^a   MacKenzie, Roger ^a   Zhang, Jianbing ^a  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

(Chimeric) heavy chain antibody; Epidermal growth factor receptor; Single domain antibody

Indexed keywords

CHIMERIC ANTIBODY; CONTRAST MEDIUM; COPPER 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID SINGLE DOMAIN ANTIBODY EG2; COPPER 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID SINGLE DOMAIN ANTIBODY EG2 IMMUNOGLOBULIN FC FRAGMENT FUSION PROTEIN CU 64; COPPER 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID SINGLE DOMAIN ANTIBODY EG2 MUTANT SHIGA TOXIN B SUBUNIT FUSION PROTEIN; EPIDERMAL GROWTH FACTOR; HYBRID PROTEIN; IMMUNOGLOBULIN HEAVY CHAIN; PROTEIN ANTIBODY; SINGLE DOMAIN ANTIBODY EG2; SINGLE DOMAIN ANTIBODY EG2 IMMUNOGLOBULIN FC FRAGMENT FUSION PROTEIN; SINGLE DOMAIN ANTIBODY EG2 MUTANT SHIGA TOXIN B SUBUNIT FUSION PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY COMBINING SITE; ANTIBODY ENGINEERING; ANTIBODY LIBRARY; ARTICLE; BINDING AFFINITY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG ISOLATION; DRUG SCREENING; DRUG STABILITY; DRUG TARGETING; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; ISOTOPE LABELING; MOLECULAR SIZE; MOUSE; NEOPLASM; NONHUMAN; NUCLEOTIDE SEQUENCE; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN LOCALIZATION;

AMINO ACID SEQUENCE; ANIMALS; CAMELIDS, NEW WORLD; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; IMMUNOGLOBULIN FRAGMENTS; MALE; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PANCREATIC NEOPLASMS; PROTEIN ENGINEERING; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE ALIGNMENT;

LAMA (MAMMAL);

EID: 75949097934     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.08.003     Document Type: Article

References (45)

1. Sebastian S., Settleman J., Reshkin S.J., Azzariti A., Bellizzi A., and Paradiso A. The complexity of targeting EGFR signalling in cancer: from expression to turnover. Biochim. Biophys. Acta 1766 (2006) 120-139
2. Carpenter G. Receptors for epidermal growth factor and other polypeptide mitogens. Annu. Rev. Biochem. 56 (1987) 881-914
3. Sato J.D., Kawamoto T., Le A.D., Mendelsohn J., Polikoff J., and Sato G.H. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol. Biol. Med. 1 (1983) 511-529
4. Jain M., Chauhan S.C., Singh A.P., Venkatraman G., Colcher D., and Batra S.K. Penetratin improves tumor retention of single-chain antibodies: a novel step toward optimization of radioimmunotherapy of solid tumors. Cancer Res. 65 (2005) 7840-7846
5. Trejtnar F., and Laznicek M. Analysis of renal handling of radiopharmaceuticals. Quart. J. Nucl. Med. 46 (2002) 181-194
6. Goel A., Colcher D., Baranowska-Kortylewicz J., Augustine S., Booth B.J., Pavlinkova G., et al. Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application. Cancer Res. 60 (2000) 6964-6971
7. Hu S., Shively L., Raubitschek A., Sherman M., Williams L.E., Wong J.Y., et al. Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res. 56 (1996) 3055-3061
8. Adams G.P., Schier R., McCall A.M., Simmons H.H., Horak E.M., Alpaugh R.K., et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 61 (2001) 4750-4755
9. Wu A.M., Tan G.J., Sherman M.A., Clarke P., Olafsen T., Forman S.J., et al. Multimerization of a chimeric anti-CD20 single-chain Fv-Fc fusion protein is mediated through variable domain exchange. Protein Eng. 14 (2001) 1025-1033
10. Kenanova V., Olafsen T., Williams L.E., Ruel N.H., Longmate J., Yazaki P.J., et al. Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy. Cancer Res. 67 (2007) 718-726
11. To R., Hirama T., Arbabi-Ghahroudi M., MacKenzie R., Wang P., Xu P., et al. Isolation of monomeric human V(H)s by a phage selection. J. Biol. Chem. 280 (2005) 41395-41403
12. Jespers L., Schon O., Famm K., and Winter G. Aggregation-resistant domain antibodies selected on phage by heat denaturation. Nat. Biotechnol. 22 (2004) 1161-1165
13. Hamers-Casterman C., Atarhouch T., Muyldermans S., Robinson G., Hamers C., Songa E.B., et al. Naturally occurring antibodies devoid of light chains. Nature 363 (1993) 446-448
14. Greenberg A.S., Avila D., Hughes M., Hughes A., McKinney E.C., and Flajnik M.F. A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks. Nature 374 (1995) 168-173
15. Revets H., De Baetselier P., and Muyldermans S. Nanobodies as novel agents for cancer therapy. Expert Opin. Invest. Drugs 5 (2005) 111-124
16. Dumoulin M., Conrath K., Van Meirhaeghe A., Meersman F., Heremans K., Frenken L.G., et al. Single-domain antibody fragments with high conformational stability. Protein Sci. 11 (2002) 500-515
17. Arbabi Ghahroudi M., Desmyter A., Wyns L., Hamers R., and Muyldermans S. Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett. 414 (1997) 521-526
18. Li S., Zheng W., Kuolee R., Hirama T., Henry M., Makvandi-Nejad S., et al. Pentabody-mediated antigen delivery induces antigen-specific mucosal immune response. Mol. Immunol. 46 (2009) 1718-1726
19. Davies J., and Riechmann L. Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen binding. Immunotechnology 2 (1996) 169-179
20. De Genst E., Handelberg F., Van Meirhaeghe A., Vynck S., Loris R., Wyns L., et al. Chemical basis for the affinity maturation of a camel single domain antibody. J. Biol. Chem. 279 (2004) 53593-53601
21. Cortez-Retamozo V., Lauwereys M., Hassanzadeh Gh G., Gobert M., Conrath K., Muyldermans S., et al. Efficient tumor targeting by single-domain antibody fragments of camels. Int. J. Cancer 98 (2002) 456-462
22. Cortez-Retamozo V., Backmann N., Senter P.D., Wernery U., De Baetselier P., Muyldermans S., et al. Efficient cancer therapy with a nanobody-based conjugate. Cancer Res. 64 (2004) 2853-2857
23. Miao Q.F., Liu X.Y., Shang B.Y., Ouyang Z.G., and Zhen Y.S. An enediyne-energized single-domain antibody-containing fusion protein shows potent antitumor activity. Anticancer Drugs 18 (2007) 127-137
24. Roovers R.C., Laeremans T., Huang L., De Taeye S., Verkleij A.J., Revets H., et al. Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR nanobodies. Cancer Immunol. Immunother. 56 (2007) 303-317
25. Omidfar K., Rasaee M.J., Modjtahedi H., Forouzandeh M., Taghikhani M., and Golmakani N. Production of a novel camel single-domain antibody specific for the type III mutant EGFR. Tumour Biol. 25 (2004) 296-305
26. Gainkam L.O., Huang L., Caveliers V., Keyaerts M., Hernot S., Vaneycken I., et al. Comparison of the biodistribution and tumor targeting of Two 99mTc-labeled Anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J. Nucl. Med. 49 (2008) 788-795
27. Huang L., Gainkam L.O., Caveliers V., Vanhove C., Keyaerts M., De Baetselier P., et al. SPECT imaging with (99 m)Tc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. Mol. Imaging Biol. 10 (2008) 167-175
28. Brown P.M., Debanne M.T., Grothe S., Bergsma D., Caron M., Kay C., et al. The extracellular domain of the epidermal growth factor receptor, Studies on the affinity and stoichiometry of binding, receptor dimerization and a binding-domain mutant. Eur. J. Biochem. 225 (1994) 223-233
29. Campa M.J., Kuan C.T., O'Connor-McCourt M.D., Bigner D.D., and Patz Jr. E.F. Design of a novel small peptide targeted against a tumor-specific receptor. Biochem. Biophys. Res. Commun. 275 (2000) 631-636
30. Tanha J., Muruganandam A., and Stanimirovic D. Phage display technology for identifying specific antigens on brain endothelial cells. Methods Mol. Med. 89 (2003) 435-449
31. Stone E., Hirama T., Tanha J., Tong-Sevinc H., Li S., MacKenzie C.R., et al. The assembly of single domain antibodies into bispecific decavalent molecules. J. Immunol. Methods 318 (2007) 88-94
32. Zhang J., Li Q., Nguyen T.D., Tremblay T.L., Stone E., To R., et al. A pentavalent single-domain antibody approach to tumor antigen discovery and the development of novel proteomics reagents. J. Mol. Biol. 341 (2004) 161-169
33. Durocher Y., Perret S., and Kamen A. High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res. 30 (2002) E9
34. Zhang J., Liu X., Bell A., To R., Baral T.N., Azizi A., et al. Transient expression and purification of chimeric heavy chain antibodies. Protein Expression Purif. 65 (2009) 77-82
35. Pham P.L., Perret S., Cass B., Carpentier E., St-Laurent G., Bisson L., et al. Transient gene expression in HEK293 cells: peptone addition posttransfection improves recombinant protein synthesis. Biotechnol. Bioeng. 90 (2005) 332-344
36. Gill S.C., and Von Hippel P.H. Calculation of protein extinction coefficients from amino acid sequence data. Anal. Biochem. 182 (1989) 319-326
37. Sakaue G., Hiroi T., Nakagawa Y., Someya K., Iwatani K., Sawa Y., et al. HIV mucosal vaccine: nasal immunization with gp160-encapsulated hemagglutinating virus of Japan-liposome induces antigen-specific CTLs and neutralizing antibody responses. J. Immunol. 170 (2003) 495-502
38. Ling H., Boodhoo A., Hazes B., Cummings M.D., Armstrong G.D., Brunton J.L., et al. Structure of the shiga-like toxin I B-pentamer complexed with an analogue of its receptor Gb3. Biochemistry 37 (1998) 1777-1788
39. Luo F.R., Yang Z., Dong H., Camuso A., McGlinchey K., Fager K., et al. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft. Cancer Chemother. Pharmacol. 56 (2005) 455-464
40. Graff C.P., and Wittrup K.D. Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res. 63 (2003) 1288-1296
41. Xu X., Clarke P., Szalai G., Shively J.E., Williams L.E., Shyr Y., et al. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein. Cancer Res. 60 (2000) 4475-4484
42. Slavin-Chiorini D.C., Kashmiri S.V., Schlom J., Calvo B., Shu L.M., Schott M.E., et al. Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins. Cancer Res. 55 (1995) 5957s-5967s
43. Khawli L.A., Biela B., Hu P., and Epstein A.L. Comparison of recombinant derivatives of chimeric TNT-3 antibody for the radioimaging of solid tumors. Hybrid Hybridom. 22 (2003) 1-9
44. Buchegger F., Haskell C.M., Schreyer M., Scazziga B.R., Randin S., Carrel S., et al. Radiolabeled fragments of monoclonal antibodies against carcinoembryonic antigen for localization of human colon carcinoma grafted into nude mice. J. Exp. Med. 158 (1983) 413-427
45. Jespers L., Schon O., James L.C., Veprintsev D., and Winter G. Crystal structure of HEL4, a soluble, refoldable human V(H) single domain with a germ-line scaffold. J. Mol. Biol. 337 (2004) 893-903